表紙
市場調查報告書

關注市場分析:子宮癌

Market Spotlight: Uterine Cancer

出版商 Datamonitor Healthcare 商品編碼 603896
出版日期 內容資訊 英文 45 Pages
商品交期: 最快1-2個工作天內
價格
本報告書已不再販售
關注市場分析:子宮癌 Market Spotlight: Uterine Cancer
出版日期: 2019年12月04日內容資訊: 英文 45 Pages

本報告已在2020年6月4日停止出版

簡介

全球女性人口的子宮癌的發病數預計從2016年的335,200件,至2025年增加到367,300件。

本報告提供全球子宮癌的市場調查,疾病的背景、概要,發病數的十年預測,主要的治療方法,開發平台趨勢,授權、資產收購等主要交易趨勢,專利資訊,臨床試驗狀況等彙整資料。

要點

疾病的背景

治療

  • 外科治療
  • 放射治療
  • 化療
  • 荷爾蒙療法
  • 緩和照護

流行病學

開發平台藥物

授權、資產收購等的交易

本源專利

臨床試驗環境

  • 贊助商:各進展狀況
  • 贊助商:各階段

文獻

附錄

目錄

This Market Spotlight report covers the uterine cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 385,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 404,300 incident cases by

2028. In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by

2028. Merck & Co's Keytruda and Eisai's Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes, respectively.

The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in the NDA/BLA stage.

Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.

High-impact upcoming events for the drugs in the uterine cancer space comprise topline Phase II trial results for XBIO-101, and an estimated PDUFA date for dostarlimab.

The overall likelihood of approval of a Phase I solid tumors asset is 5.7%, and the average probability a drug advances from Phase III is 41.9%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been nine licensing and asset acquisition deals involving endometrial cancer drugs during 2015-20. The $1,119m exclusive licensing agreement signed in 2016 between Exelixis and Ipsen, pursuant to which Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside the US, Canada and Japan, was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 95% of trials in Phase I-II, and only 5% in Phase III-IV.

The US has a substantial lead in the number of uterine neoplasms clinical trials globally, while France, Germany, Spain, and the UK lead the major European markets.

Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.

AstraZeneca leads the industry sponsors with the highest overall number of clinical trials for uterine neoplasms

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

9 TREATMENT

9 Surgery

9 Radiation therapy

9 Chemotherapy

10 Hormone therapy

10 Palliative care

11 EPIDEMIOLOGY

15 MARKETED DRUGS

17 PIPELINE DRUGS

23 RECENT EVENTS AND ANALYST OPINION

23 MGA012 for Uterine Cancer (July 2, 2019)

23 Sacituzumab Govitecan for Uterine Cancer (April 29, 2019)

24 TAK-117 for Uterine Cancer (March 20, 2019)

25 Dostarlimab for Uterine Cancer (March 19, 2019)

27 DKN-01 for Uterine Cancer (March 18, 2019)

28 Dostarlimab for Uterine Cancer (October 20, 2018)

31 KEY UPCOMING EVENTS

32 KEY REGULATORY EVENTS

32 Dostarlimab Submitted For (Relatively) Broad Endometrial Cancer Indication

32 FDA Issues Pair Of RTOR Approvals To Keytruda/Lenvima Combo, Erleada

32 Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

33 PROBABILITY OF SUCCESS

34 LICENSING AND ASSET ACQUISITION DEALS

34 Deals Shaping The Medical Industry, August 2019

35 PARENT PATENTS

36 REVENUE OPPORTUNITY

37 CLINICAL TRIAL LANDSCAPE

38 Sponsors by status

39 Sponsors by phase

41 BIBLIOGRAPHY

41 Prescription Information

42 APPENDIX

LIST OF FIGURES

  • 13 Figure 1: Trends in incident cases of uterine cancer, 2019-28
  • 17 Figure 2: Overview of pipeline drugs for uterine cancer in the US
  • 17 Figure 3: Pipeline drugs for uterine cancer, by company
  • 18 Figure 4: Pipeline drugs for uterine cancer, by drug type
  • 18 Figure 5: Pipeline drugs for uterine cancer, by classification
  • 27 Figure 6: Dostarlimab for Uterine Cancer (March 19, 2019): Phase I/II - GARNET
  • 28 Figure 7: DKN-01 for Uterine Cancer (March 18, 2019): Phase II - Gynecologic Malignancies (P204)
  • 30 Figure 8: Dostarlimab for Uterine Cancer (October 20, 2018): Phase I/II - GARNET
  • 31 Figure 9: Key upcoming events in uterine cancer
  • 33 Figure 10: Probability of success in the uterine cancer pipeline
  • 34 Figure 11: Licensing and asset acquisition deals in uterine cancer, 2015-20
  • 35 Figure 12: Parent patents in uterine cancer
  • 37 Figure 13: Clinical trials in uterine cancer
  • 37 Figure 14: Top 10 drugs for clinical trials in uterine cancer
  • 38 Figure 15: Top 10 companies for clinical trials in uterine cancer
  • 38 Figure 16: Trial locations in uterine cancer
  • 39 Figure 17: Uterine cancer trials status
  • 40 Figure 18: Uterine cancer trials sponsors by phase

LIST OF TABLES

  • 12 Table 1: Incident cases of uterine cancer, 2019-28
  • 14 Table 2: Five-year prevalent cases of uterine cancer, 2019-28
  • 16 Table 3: Marketed drugs for uterine cancer
  • 19 Table 4: Pipeline drugs for uterine cancer in the US
  • 23 Table 5: MGA012 for Uterine Cancer (July 2, 2019)
  • 24 Table 6: Sacituzumab Govitecan for Uterine Cancer (April 29, 2019)
  • 25 Table 7: TAK-117 for Uterine Cancer (March 20, 2019)
  • 26 Table 8: Dostarlimab for Uterine Cancer (March 19, 2019)
  • 27 Table 9: DKN-01 for Uterine Cancer (March 18, 2019)
  • 29 Table 10: Dostarlimab for Uterine Cancer (October 20, 2018)
  • 36 Table 11: Historical global sales, by drug ($m), 2014-18
  • 36 Table 12: Forecasted global sales, by drug ($m), 2020-24